Category: InVivo Therapeutics Corp.Syndicate content

InVivo hits the NASDAQ exchange

April 17, 2015 by Val Kennedy

Shares of InVivo Therapeutics are slated to begin trading today on the NASDAQ stock exchange.

InVivo shares to trade Friday on Nasdaq Capital Market

InVivo Therapeutics adds 4th clinical site

March 30, 2015 by Brad Perriello

InVivo Therapeutics adds the 4th site to a feasibility study of its biodegradable implant to treat acute spinal cord injuries.

InVivo Therapeutics adds 4th clinical site

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

InVivo adds 3rd site to clinical trial

March 26, 2015 by Mark Hollmer

InVivo Therapeutics adds a 3rd clinical site to a feasibility study of its biodegradable implant to treat acute spinal cord injuries.

InVivo adds 3rd site to clinical trial

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

InVivo Therapeutics readies reverse split ahead of NASDAQ listing

March 24, 2015 by Brad Perriello

InVivo Therapeutics readies a 1-for-4 reverse stock split ahead of a planned listing on the NASDAQ stock exchange.

InVivo Therapeutics readies reverse split ahead of NASDAQ listing

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

RIP former Evalve CEO Powell | Personnel Moves

March 23, 2015 by Brad Perriello

Ferolyn Powell, the former CEO of Evalve who led it to a $410 million acquisition by Abbott, is killed in a motorbike accident in Thailand.

RIP former Evalve CEO Powell | Personnel Moves

Former Evalve CEO Ferolyn Powell, who led the MitraClip developer to a $410 million acquisition by Abbott (NYSE:ABT), died this month in a motorbike accident in northern Thailand, her family said yesterday.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

InVivo Therapeutics reports narrowed 2014 losses

March 16, 2015 by Val Kennedy

InVivo Therapeutics reports narrowed annual losses, due in part to changes in the market value of the company's derivative warrant liability.

InVivo Therapeutics reports narrowed losses

(OTC:IVOB) reported a narrowed annual loss, due in part to changes in the market value of the company's derivative warrant liability.

InVivo Therapeutics looks to raise $12m for spine trial

February 2, 2015 by Mark Hollmer

Massachusetts-based InVivo Therapeutics looks to raise $12 million in a direct offering as it enrolls the 2nd patient in a feasibility trial for its neuro-spinal scaffold.

InVivo Therapeutics looks to raise $12 for spine trial